Document Detail


Treatment of portal hypertension.
MedLine Citation:
PMID:  22468079     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Portal hypertension is the main complication of cirrhosis and is defined as an hepatic venous pressure gradient (HVPG) of more than 5 mmHg. Clinically significant portal hypertension is defined as HVPG of 10 mmHg or more. Development of gastroesophageal varices and variceal hemorrhage are the most direct consequence of portal hypertension. Over the last decades significant advancements in the field have led to standard treatment options. These clinical recommendations have evolved mostly as a result of randomized controlled trials and consensus conferences among experts where existing evidence has been reviewed and future goals for research and practice guidelines have been proposed. Management of varices/variceal hemorrhage is based on the clinical stage of portal hypertension. No specific treatment has shown to prevent the formation of varices. Prevention of first variceal hemorrhage depends on the size/characteristics of varices. In patients with small varices and high risk of bleeding, non-selective β-blockers are recommended, while patients with medium/large varices can be treated with either β-blockers or esophageal band ligation. Standard of care for acute variceal hemorrhage consists of vasoactive drugs, endoscopic band ligation and antibiotics prophylaxis. Transjugular intrahepatic portosystemic shunt (TIPS) is reserved for those who fail standard of care or for patients who are likely to fail ("early TIPS"). Prevention of recurrent variceal hemorrhage consists of the combination of β-blockers and endoscopic band ligation.
Authors:
Khurram Bari; Guadalupe Garcia-Tsao
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  World journal of gastroenterology : WJG     Volume:  18     ISSN:  2219-2840     ISO Abbreviation:  World J. Gastroenterol.     Publication Date:  2012 Mar 
Date Detail:
Created Date:  2012-04-02     Completed Date:  2012-05-15     Revised Date:  2014-05-20    
Medline Journal Info:
Nlm Unique ID:  100883448     Medline TA:  World J Gastroenterol     Country:  China    
Other Details:
Languages:  eng     Pagination:  1166-75     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adrenergic beta-Antagonists / therapeutic use
Animals
Clinical Trials as Topic
Consensus Development Conferences as Topic
Esophageal and Gastric Varices / complications
Gastrointestinal Hemorrhage / etiology,  therapy
Humans
Hypertension, Portal / therapy*
Ligation
Portasystemic Shunt, Transjugular Intrahepatic
Chemical
Reg. No./Substance:
0/Adrenergic beta-Antagonists
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Management of non-variceal upper gastrointestinal tract hemorrhage: controversies and areas of uncer...
Next Document:  Management of portal hypertension in children.